Bioventus Inc.’s pain-treatment portfolio did the heavy lifting in the third quarter, producing enough growth to offset weaker bone-stimulation sales and keep companywide revenue moving forward. The Durham, North Carolina, company also paid down debt while continuing a strategic review that could reshape its future.
Company News Premium
Bioventus Announces Q3 Results and Strategic Buyer Interest

#bioventus3Q26 earnings report
Author
React:
